Description

GeoVax Labs, Inc. is a clinical-stage biotechnology firm dedicated to creating human vaccines and immunotherapies. The company's core mission involves tackling a range of infectious diseases and various solid tumor cancers. Their innovative approach is centered on a proprietary modified vaccinia ankara virus-like particle (MVA-VLP) vaccine platform. The company's pipeline includes diverse preventive vaccine candidates aimed at combating critical pathogens such as COVID-19, human immunodeficiency virus (HIV), Zika virus, malaria, and hemorrhagic fever viruses like Ebola, Sudan, Marburg, and Lassa. In parallel, GeoVax is advancing therapeutic vaccines designed to address existing conditions, including HIV, chronic Hepatitis B infections, and solid tumor malignancies. Key programs include GEO-CM04S1, a COVID-19 preventive vaccine candidate currently in Phase 2 clinical trials, and Gedeptin, a novel, patented product in Phase 1/2 clinical trials for treating advanced head and neck squamous cell carcinoma, which is also being explored for broader solid tumor applications. Additionally, the company is developing GEO-CM02, a pan-coronavirus vaccine. The preclinical stage features several other promising candidates, such as GEO-ZM02 for Zika, GEO-MM02 for malaria, GEO-EM01 for fever viruses (Ebola, Sudan, and Marburg), and GEO-LM01 targeting Lassa fever. GeoVax maintains strategic collaborations and partnership agreements with prominent institutions, including the National Institute of Allergy and Infectious Diseases (NIAID) within the National Institutes of Health, the U.S. Department of Defense, Emory University, and the Burnet Institute. Established in 1988, GeoVax Labs, Inc. operates from its headquarters in Smyrna, Georgia.